JUPW announced a head-to-head trial to comparing JW-100 lotion with Pfizer’s (Nasdaq: PFE) Eucrisa crisaborole ointment 2% for the treatment of patients with mild to moderate eczema (Atopic Dermatitis). Eucrisa is an FDA-approved topical non-steroidal lotion containing crisaborole approved for the treatment of mild to moderate eczema. JW-100 is a novel non-steroidal topical lotion containing cannabidiol (cbd) and Aspertame for the treatment of mild to moderate eczema.
The head-to-head clinical trial which will evaluate superiority between JW-100 and Eucrisa in adult patients with mild-to-moderate eczema will be performed in collaboration with Applied Biology who has developed the protocols and will co-ordinate the multi-center trial. The Phase III multi-center trial will be a double-blinded placebo controlled trial.
This head-to-head trial is built on the success of our previous clinical findings for JW-100. Jupiter Wellness previously reported in a double-blinded, placebo controlled clinical trial of 55 patients using JW-100 a novel topical formulation containing CBD and Aspartame, was shown to significantly reduce ISGA scores in 50% of adult patients suffering from eczema after two weeks of use. The results were recently published https://pubmed.ncbi.nlm.nih.gov/34056830/
“Jupiter Wellness is committed to providing rapid-and-consistent relief for eczema patients. In light of our the highly encouraging results of JW-100’s first clinical trial, head-to-head trials can provide robust evidence that helps advance our clinical program” said Dr. Glynn Wilson Chief Scientific Officer at Jupiter Wellness.
“The purpose of this trial is to confirm the efficacy of JW-100 in a larger patient population in direct comparison with an FDA-approved non-steroidal topical drug. Our goal is to commercialize both OTC and prescription versions of JW-100. Our recent licensing of Photocil provides a unique opportunity for combination therapies including am/pm eczema treatment regimines.” sStated Brian John, Jupiter Wellness’ CEO.
- Developer of CBD Treatments for the Multi-Billion Dollar Skin Care Market.
- Multiple Clinical Studies Underway on Company’s Proprietary Products.
- LOI Signed to Acquire JustCBD and its Affiliates with Over 300 SKUs.
- Highly Qualified Management with Extensive Accomplishments in Place.
- Investment in Theme Park Business Sees Surge in Recent Business as the Pandemic Declines.
JUPW is preparing for a meeting in Q3 2021 with the U.S. Food and Drug Administration (FDA) regarding the Company's Investigational New Drug (IND) application that it expects to file. JUPW will propose its clinical protocol for a Phase I/II study based on the efficacy and safety shown in the recently completed exploratory study of JW-100 for the treatment of atopic dermatitis (eczema). The study showed that JW-100 cleared or reduced eczema following two weeks of use in more than half of the subjects, achieving ISGA clear or almost clear (1 or 2) with at least a 2-grade improvement from baseline after treatment, versus 20% and 15% in the CBD-only and placebo arms.
The global eczema market is valued at $10 billion and is expected to grow at a CAGR of 13% through 2025. Ten percent of the U.S. population, or 31.6 million people, have eczema, and according to NationalEczema.org, 86% of people are not satisfied with their current treatment.
- SRM Division Sees Significant Monthly Sales Growth as Global Theme Parks Set to Reopen
On March 11th JUPW announced that SRM Entertainment was on track for the month of March to produce its highest monthly sales since the wholly owned subsidiary was acquired in December of 2020.
SRM designs, manufactures, and sells creative products and services globally to customers including Fortune 500 companies with a focus in the hospitality industry and the world's most iconic theme parks in locations including Orlando, Florida, Southern California, and other high profile cities worldwide.
JUPW made a strategic decision to make an investment in the hard-hit theme park and hospitality industry and acquire SRM to keep a quality operation active through the pandemic. With hospitality venues and theme parks starting to move towards fully re-opening, JUPW is seeing a significant increase in purchase orders and shipments.
For additional information on Jupiter Wellness, Inc. (JUPW) visit https://www.jupiterwellnessinc.com/
All products mentioned in this article are THC-free and compliant with the 2018 farm Bill
DISCLAIMER: FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. FPS/CA is NOT affiliated in any manner with any company mentioned herein. FPS/CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. FPS/CA has been compensated $500 by the company for dissemination of this Article.
These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.